Atomi Financial Group Inc. Has $1.08 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Atomi Financial Group Inc. increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 10.4% during the fourth quarter, Holdings Channel reports. The fund owned 6,651 shares of the company’s stock after acquiring an additional 626 shares during the quarter. Atomi Financial Group Inc.’s holdings in Zoetis were worth $1,084,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis in the third quarter valued at $31,000. First Personal Financial Services purchased a new stake in Zoetis in the 3rd quarter worth about $33,000. Capital Performance Advisors LLP acquired a new stake in Zoetis during the 3rd quarter worth about $33,000. Dunhill Financial LLC grew its stake in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Finally, Quarry LP increased its holdings in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.5 %

Shares of Zoetis stock opened at $166.64 on Thursday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The stock has a 50 day moving average price of $170.60 and a two-hundred day moving average price of $179.89. The stock has a market capitalization of $75.18 billion, a P/E ratio of 31.32, a PEG ratio of 2.55 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.36 EPS. Equities analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. The ex-dividend date of this dividend is Tuesday, January 21st. This is a boost from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is currently 32.52%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners assumed coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, UBS Group started coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.